Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Eligibility Criteria

• * General:
• 1. Must be willing and able to provide written, signed informed consent.
• 2. Age: Subjects ≥ 50 and ≤ 89 years of age at the time of signing the informed consent
• 3. Diagnosis of wAMD, including symptomatic macular PCV, confirmed by the Central Reading Center
• 4. The macular neovascularization lesion must be confirmed as determined by the Central Reading Center based on SD-OCT imaging at screening.
• 5. BCVA ≤ 20/32 and ≥ 20/250 (≤ 78L and ≥ 30L ETDRS letters)
• 6. History of ≥ 2 anti-VEGF injections prior to trial entry with meaningful response to anti-VEGF and continued need for anti-VEGF treatment
• 7. Response to anti-VEGF at trial entry
• 8. Must be pseudophakic
• * Study or Fellow Eye:
• 1. Prior gene therapy, either eye
• 2. Any active ocular/intraocular infection or inflammation (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, uveitis) or history of idiopathic or autoimmune-associated uveitis, either eye
• 3. History of retinal disease other than wAMD or PCV, study eye
• 4. Any condition preventing visual acuity improvement (e.g., fibrosis, atrophy, or retinal epithelial tear in the center of the fovea), study eye.
• 5. History of (or active) retinal detachment, study eye
• 6. Uncontrolled glaucoma (defined as IOP \> 25 mmHg despite treatment), study eye, or history of steroid-response ocular hypertension/glaucoma in either eye
• 7. History of intravitreal therapy, (other than anti-VEGF therapy) such as intravitreal steroid injection or investigational product, in the 6 months prior to screening, study eye
• 8. Any prior treatment with photodynamic therapy or laser photocoagulation, study eye
• 9. History of glaucoma filtration, vitrectomy, or other procedure that could affect drug distribution or clearance, study eye.